LTR Pharma is a Clinical Stage Biopharmaceutical Company
Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.
SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects
LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years
worldwide expected cases by 2025
minute effectiveness
projected global market value 2024
ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.
LTR Pharma has received the final Clinical Study Report for its SPONTAN® Phase II pharmacokinetic study. The report completes the pharmacokinetic dataset agreed with the FDA for LTR Pharma’s planned U.S. 505(b)(2) submission. LTR’s SPONTAN® is a fast-acting intranasal spray for the treatment of erectile dysfunction, enabling an onset of
LTR Pharma has entered into an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, a US pharmaceutical company focused on men’s health, to introduce Marius’ lead product, KYZATREX® (testosterone undecanoate oral capsules), in Australia. KYZATREX is FDA-approved and commercially available in the United States. Strategic rationale Testosterone deficiency affects energy, mood,
LTR Pharma has executed a definitive Compounding and Supply Agreement with Strive Specialties Inc., a leading U.S. Section 503A compounding pharmacy, converting the previously announced binding Term Sheet into a definitive commercial agreement governing the planned manufacturing, compounding, fulfilment and nationwide supply of ROXUS® in the United States. The agreement establishes the operational framework for
SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.